Legal status in the United States

Is GHRP-2 legal?

Read at FDA, DEA and WADAPublished by PepVault

GHRP-2 has no FDA-approved product, is not a federally controlled substance, and is banned in sport (WADA names it under S2.2.4), as of November 18, 2026.

GHRP-2 at a glance

CheckStatus, read Nov 18, 2026
FDA approvalNot approved
CompoundingSafety-risk list for outsourcing facilities (503B category 2)
DEA scheduleNot controlled
Sport (WADA)Banned, named (S2.2.4)

FDA approval

GHRP-2 (pralmorelin) has no FDA-approved product: Drugs@FDA lists no application for it.

A smiling man in a grey t-shirt in his living room, holding his phone

PepVault for iPhone

Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Compounding

FDA keeps GHRP-2, for injection and nasal use, in 503B category 2 (outsourcing facilities) since September 29, 2023: bulk substances that may raise significant safety risks. For pharmacies it sits in 503A category 3, substances nominated without adequate support.

The source: “Growth hormone releasing peptide-2 (GHRP-2)”

DEA schedule

It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.

Sport (WADA)

WADA bans GHRP-2 at all times, in and out of competition: the 2026 list names it among the GH-releasing peptides under S2.2.4.

The source: “GHRP-2 (pralmorelin)”

How it is sold when it isn’t approved

FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.

The source: falsely labeled “for research purposes” or “not for human consumption.”

What this means and doesn’t

This page reports what the agencies’ own pages said about GHRP-2 in the United States when we read them on November 18, 2026. These are records of regulators, not study evidence; for what the research shows, see the compound page.

It is not legal advice, and it doesn’t cover state laws or other countries, whose rules differ. Agencies change their lists, so each fact carries its date and a link to the page it came from.

Questions

  • Is GHRP-2 FDA approved?

    GHRP-2 (pralmorelin) has no FDA-approved product: Drugs@FDA lists no application for it.

  • Is GHRP-2 a controlled substance?

    It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.

  • Is GHRP-2 banned in sport?

    WADA bans GHRP-2 at all times, in and out of competition: the 2026 list names it among the GH-releasing peptides under S2.2.4.

  • What does FDA say about compounding GHRP-2?

    FDA keeps GHRP-2, for injection and nasal use, in 503B category 2 (outsourcing facilities) since September 29, 2023: bulk substances that may raise significant safety risks. For pharmacies it sits in 503A category 3, substances nominated without adequate support.

  • What does FDA say about the “research use only” label?

    FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.

Read next

Track it in the app

PepVault for iPhone

Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo